Brian Labadie

发表

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

A. Patnaik, A. Swarbrick, Xiaobing Fan, 2022, bioRxiv.

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

G. Schwartz, P. Munster, D. Hogg, 2019, Clinical Cancer Research.

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

A. Bryce, A. Patnaik, W. Abida, 2022, Cancer management and research.

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

J. Luke, R. Bao, Brian Labadie, 2018, Clinical Cancer Research.

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

T. Hensing, T. Karrison, R. Brisson, 2017, Oncotarget.

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

J. Messina, J. Luke, J. Zager, 2018, Clinical & Experimental Metastasis.

Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.

C. Zachary, J. Gandy, Brian Labadie, 2017, Journal of drugs in dermatology : JDD.

Targeting Innate Immunity in Cancer Therapy

A. Patnaik, Brian Labadie, Srikrishnan Rameshbabu, 2021, Vaccines.

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

A. Balar, J. Luke, Brian Labadie, 2021, Cancers.

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

A. Balar, Ping Liu, I. Durán, 2019, Journal of Translational Medicine.

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

G. Schwartz, P. Munster, D. Hogg, 2020, Melanoma research.

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

V. Sondak, T. Karrison, D. Olson, 2020 .

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

V. Sondak, T. Karrison, D. Olson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers.

A. Fojo, Brian Labadie, 2023, JAMA Oncology.

Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis

M. Loda, Xiaobing Fan, K. Chaudagar, 2023, bioRxiv.

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

A. Balar, Ping Liu, I. Durán, 2019, Journal of Translational Medicine.

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

J. Messina, J. Luke, J. Zager, 2018, Clinical & Experimental Metastasis.

Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosis

K. Chaudagar, Brian Labadie, Taghreed Hirz, 2023, bioRxiv.